Cancer Health Forums

Breast Cancer Forums => Living with Breast Cancer => Topic started by: Cancer Health Editors on January 23, 2020, 11:06:36 am

Title: For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge
Post by: Cancer Health Editors on January 23, 2020, 11:06:36 am
Two new treatment options are emerging for women with metastatic breast cancer, following positive results from clinical trials. The trials tested the drugs tucatinib and trastuzumab deruxtecan (Enhertu) in women who had been previously treated for metastatic breast cancer that overproduces the HER2 protein, known as HER2-positive breast cancer.

In one of the trials, called HER2CLIMB, women treated with tucatinib in addition to trastuzumab (Herceptin) and capecitabine lived longer both without their disease progressing and overall than women who received only trastuzumab and capecitabine (Xeloda). The treatment also benefited women in the trial whose cancer had spread to the brain, a particularly challenging group to treat.

Trastuzumab deruxtecan was tested in a smaller trial, called DESTINY-Breast01, and wasn’t compared directly with another treatment. But many women in the study who received the drug saw their tumors shrink and lived for an extended period without their cancer getting worse.

Click here to read more...
https://www.cancerhealth.com/blog/metastatic-her2positive-breast-cancer-new-treatments-emerge